trial · primary record
Tislelizumab
Esophageal Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 172 |
| Primary completion | 2034-05-30 |
| Primary endpoint | Recurrence-free survival as assessed by the investigator |
| Registry ID | NCT06914011 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:49.077Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06914011
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.